Patient disposition
A total of 35 patients with a median age of 63.0 (range 42–84) years were enrolled and all these patients were included in the FAS and the safety analysis set. Of the 35 patients, 15 patients (42.9%) had received immune-oncology (IO) agents. Twenty-four (68.6%) patients had received one prior VEGFR-TKI and eight (22.9%) patients had received two. The most common prior VEGFR-TKI therapies in the total patient group were sunitinib (68.6%) and axitinib (51.4%).Baseline IMDC risk scores were favorable for 6 (17.1%) patients, intermediate for 22 (62.9%) patients, and poor for 7 (20%) patients [